Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CTLA-4 IgG2a
- Development stage
- Preclinical
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Anti-CTLA-4 IgG2a is a monoclonal antibody targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), an immune checkpoint receptor that inhibits T cell activation. The IgG2a isotype is used primarily in preclinical mouse models and is characterized by an Fc region that confers strong antibody-dependent cellular cytotoxicity (ADCC) and the ability to deplete intratumoral regulatory T cells (Tregs) via engagement of Fc gamma receptors on macrophages, enhancing the Teffector:Treg cell ratio and promoting antitumor immune responses[3][4][5]. Its mechanism includes CTLA-4 blockade, leading to enhanced T cell activity and selective Treg depletion within tumors, with activity highly dependent on Fc-FcγR interactions[3][4][5]. It is considered a tool compound for experimental cancer immunotherapy.
- Other names
- anti–CTLA-4 IgG2amurine anti-CTLA-4 IgG2aclone 9D9clone9D9clone-9D9
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)
Beyond the preview
Go deeper on anti-CTLA-4 IgG2a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CTLA-4 IgG2a.